AbbVie Inc (ABBV)vsCollegium Pharmaceutical Inc (COLL)
ABBV
AbbVie Inc
$294.48
-0.18%
HEALTHCARE · Cap: $521.11B
COLL
Collegium Pharmaceutical Inc
$24.95
+0.56%
HEALTHCARE · Cap: $770.98M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 7998% more annual revenue ($66.01B vs $815.19M). ABBV leads profitability with a 15.7% profit margin vs 4.7%. ABBV appears more attractively valued with a PEG of 0.60. ABBV earns a higher WallStSmart Score of 77/100 (B+).
ABBV
Strong Buy77
out of 100
Grade: B+
COLL
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-85.2%
Fair Value
$157.29
Current Price
$294.48
$137.19 premium
Margin of Safety
+88.3%
Fair Value
$384.11
Current Price
$24.95
$359.16 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 37.2%
Earnings expanding 2282.0% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 22.9%
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
3.3% revenue growth
Smaller company, higher risk/reward
4.7% margin — thin
Earnings declined 29.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 37.2%. Revenue growth of 10.3% demonstrates continued momentum.
Bull Case : COLL
The strongest argument for COLL centers on PEG Ratio, Price/Book, Operating Margin. PEG of 0.72 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.7x leaves little room for execution misses.
Bear Case : COLL
The primary concerns for COLL are Revenue Growth, Market Cap, Profit Margin. Debt-to-equity of 2.75 is elevated, increasing financial risk. Thin 4.7% margins leave little buffer for downturns.
Key Dynamics to Monitor
ABBV profiles as a mature stock while COLL is a value play — different risk/reward profiles.
COLL carries more volatility with a beta of 0.73 — expect wider price swings.
ABBV is growing revenue faster at 10.3% — sustainability is the question.
ABBV generates stronger free cash flow (7.3B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (77/100 vs 58/100), backed by strong 15.7% margins and 10.3% revenue growth. COLL offers better value entry with a 88.3% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Collegium Pharmaceutical Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and markets pain management medications. The company is headquartered in Stoughton, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?